A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Cinrebafusp alfa demonstrates promising activity in patients with HER2-positive malignancies who have progressed on prior HER2-targeting regimens. Its acceptable safety profile suggests it could be a treatment option for patients not responding to existing HER2-directed therapies. See related commentary by Eguren-Santamaría et al., p. 231.
Authors
- Cornelia Wurzenberger
- Noah M. Hahn (ORCID: https://orcid.org/0000-0002-1016-9024)
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Laura-Carolin Hasenkamp
- Rachna T. Shroff (ORCID: https://orcid.org/0000-0003-0066-2672)
- Paula Raffin Pohlmann (ORCID: https://orcid.org/0000-0001-7914-5162)
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Markus Zettl (ORCID: https://orcid.org/0000-0002-0428-0180)
- Eva-Maria Hansbauer (ORCID: https://orcid.org/0000-0003-4633-2644)
- Shane A. Olwill
- Stephen V. Liu (ORCID: https://orcid.org/0000-0002-4852-3914)
- Ingmar Bruns
- Kayti Aviano
- Anuradha Krishnamurthy
- Anthony W. Tolcher (ORCID: https://orcid.org/0000-0002-6322-9721)
- Geoffrey Y. Ku (ORCID: https://orcid.org/0000-0002-0448-1038)
- Sara A. Hurvitz (ORCID: https://orcid.org/0000-0001-7808-7191)
- Manuela Duerr
- Louis Matis (ORCID: https://orcid.org/0000-0003-3467-3089)
- Amita Patnaik (ORCID: https://orcid.org/0000-0002-4144-2193)
- Raman Kumar
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Arizona (US)
- Johns Hopkins University (US)
- Bayer (United States) (US)
- University of California, Los Angeles (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Fred Hutch Cancer Center (US)
- Urology San Antonio (US)
- Sarah Cannon (US)
- South Texas Accelerated Research Therapeutics (US)
- Pieris Pharmaceuticals (United States) (US)
- CureVac (Germany) (DE)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Tennessee Oncology (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1552
- Citations
- 10
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 4.04
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- FibroGen
- BioMarin Pharmaceutical
- Regeneron Pharmaceuticals
- Exelixis
- Jazz Pharmaceuticals
- Les Laboratories Pierre Fabre
- Astex Pharmaceuticals
- Five Prime Therapeutics
- Radius Health
- Mersana Therapeutics
- BeiGene
- Incyte
- Innovent Biologics
- NRG Oncology
- Syndax Pharmaceuticals
- SK Life Science
- NuCana
- Aminex Therapeutics
- F-star Therapeutics
- Puma Biotechnology
- Verastem Oncology
- Silverback Therapeutics
- MacroGenics
- G1 Therapeutics
- Seagen
- Eisai
- Novo Nordisk
- Sun Pharma
- Scheme for Promotion of Academic and Research Collaboration
- Plexxikon
- National Institutes of Health
- Genentech
- EMD Serono
- Chugai Pharmaceutical
- Loxo Oncology
- ImmunoMedics
- Principia Biopharma
- National Cancer Institute
- Daiichi Sankyo Europe